Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 46, Issue 10, 2005, Pages 1477-1487

  Robertson, Michael J ^a   Abonour, Rafat ^a   Hromas, Robert ^a   Nelson Jr , Robert P ^a   Fineberg, Naomi S ^a   Cornetta, Kenneth ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggressive; Autologous transplantation; Intermediate grade; Lymphoma; Transformed

Indexed keywords

ACICLOVIR; CARMUSTINE; CD34 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; NARCOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; RISK FACTOR; SECOND CANCER; TOTAL PARENTERAL NUTRITION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; CARMUSTINE; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 26944443695     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500158466     Document Type: Article

References (60)

1. Harris NL, Jaffee ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
2. Jaffe ES, Harris NL, Stein H, et al. (editors). World health organization classification of tumours: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
3. Armitage JO, Weisenburger DD. New approach to classifying the non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998;16:2780-2795.
4. Wheeler C, Strawderman M, Ayash L, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993;11:1085-1091.
5. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
6. Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for nonHodgkin's lymphoma. Biol Blood Marrow Transplant 1996;2:76-85.
7. Rapaport AP, Lifton R, Constine LS, et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1997;19:883-890.
8. Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - a Southwest Oncology Group Trial. J Clin Oncol 1998;16:48-55.
9. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma Trial. J Clin Oncol 1998;16:3264-3269.
10. Stein RS, Greer JP, Goodman S, et al. Intensified preparative regimens and autologous transplantation in relapsed and refractory intermediate grade non-Hodgkin's lymphoma. Bone Marrow Transplant 2000;25:257-262.
11. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose therapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin's lymphoma: an intention-to-treat analysis. Blood 2000;96:2399-2404.
12. Vose JM, Zhang M-J, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406-413.
13. Bolwell B, Kalaycio M, Sobecks R, et al. Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplant 2002;29:673-679.
14. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for nonHodgkin's lymphomas. J Clin Oncol 1999;17:1244-1253.
15. Surbone A, Longo DL, DeVita-Jr VT, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988;1832-1837.
16. Robertson MJ, Pelloso D, Abonour R, et al. Interleukin-12 immunotherapy after autologous stem cell transplantation for hematologic malignancies. Clin Cancer Res 2002;8:3383-3393.
17. Stamatoullas A, Fruchart C, Khalfallah S, et al. Peripheral blood stem cell transplantation for relapsed or refractory lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997;19:31-35.
18. Olivieri A, Capelli D, Montanari M, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant 2001;27:1189-1195.
19. Gopal AK, Gooley TA, Golden JB, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001;27:593-599.
20. Schouten HC, Bierman PJ, Vaughan WP, et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989;74:2579-2584.
21. Freedman AS, Takvorian T, Anderson KC, et al. Autologous bone marrow transplantation in B-cell non-Hodkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990;8:784-791.
22. Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86:3257-3262.
23. Chen CI, Crump M, Tsang R, et al. Autotransplants for histologically transformed non-Hodgkin's lymphoma. Br J Haematol 2001;113:202-208.
24. Shipp MA, Abeloff AM, Antman KH, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999;17:423-429.
25. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-1498.
26. Phillips GL, Reece DE, Wolff SN, et al. The use of conventional salvage chemotherapy before dose-intensive cytotoxic therapy and autologous transplantation for agressive-histology lymphoma: a case for re-evaluation. Leuk Lymphoma 1997;26:507-513.
27. Leonard BM, Hetu F, Busque L, et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998;91:331-339.
28. McCann JC, Kanteti R, Shilepsky B, et al. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996;2:37-43.
29. Sharp JG, Kessinger A, Mann S, et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996;14:214-219.
30. Sharp JG, Joshi SS, Armitage JO, et al. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved marrow by a culture technique. Blood 1992;79:1074-1080.
31. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002;20:2472-2479.
32. Williams CD, Goldstone AH, Pearce RM, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996;14:2454-2464.
33. Singhal S, Powles R, Treleaven J, et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000;26:489-496.
34. Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood 2000;96:4096-4102.
35. Dominietto A, Lamparelli T, Raiola AM, et al. "Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002;100:3930-3934.
36. Ketterer N, Salles G, Raba M, et al. High CD34+ cell counts decrease hematologic toxicity after autologous peripheral blood progenitor cell transplantation. Blood 1998;91:3148-3155.
37. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-3969.
38. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-3794.
39. Gazitt Y, Tian E, Barlogie B, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996;87:805-811.
40. Brugger W, Bross KJ, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636-640.
41. Jacquy C, Soree A, Lambert F, et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 2000;110: 631-637.
42. Bierman PJ, Sweetenham JW, Loberiza-Jr FR, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation - the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003;21:3744-3753.
43. Fouillard L, Laporte JP, Labopin M, et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation-results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 1998;16:2803-2816.
44. Lopez M, Lemoine FM, Firat H, et al. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphoma: different levels of tumor cell reduction. Implications for autografting. Blood 1997;90: 2830-2838.
45. Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol. Blood Marrow Transplant 2000;6:628-632.
46. Magni M, DiNicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000;96:864-869.
47. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525-1533.
48. Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002;20:2344-2352.
49. Blystad AK, Delabie J, Kvaloy S, et al. Infused CD34+ cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Brit J Haematol 2004;125:605-612.
50. Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001;19:3771-3779.
51. Abonour R, Scott KM, Kunkel LA, et al. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplant 1998;22:957-963.
52. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934-2942.
53. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005;23:461-467.
54. Klingemann H-G, Phillips GL. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 1991;8: 73-81.
55. Rapaport AP, Meisenberg B, Sarkodee-Adoo C, et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002;29:303-312.
56. Benyunes MC, Higuchi CM, York A, et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995;16:283-288.
57. Nagler A, Ackerstein A, Or R, et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997;89:3951-3959.
58. Collins Jr, RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
59. Khouri IF, Saliba R, Giralt S, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001;98:3595-3599.
60. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic stem cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777-783.